<DOC>
	<DOCNO>NCT01268293</DOCNO>
	<brief_summary>The purpose study investigate tolerability safety E7080 24 mg administer orally daily continuous dose schedule cycle ( 4 week 1 cycle ) subject solid tumor</brief_summary>
	<brief_title>A Study E7080 Subjects With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion Criteria Subjects histologically and/or cytologically diagnosis solid tumor Subjects solid tumor resistant standard antitumor therapy , appropriate treatment available Subjects whose toxicity previous treatment recover Grade 1 low toxicity ( except alopecia ) Subjects complete previous antitumor therapy least 4 week Subjects 20 year old Subjects 0 1 Performance Status Subjects agree hospitalize DLT observation Subjects adequate organ function Males female childbearing potential must agree use appropriate contraception agreement 30 day study drug administration . Agree participate study write base voluntary Exclusion Criteria Subjects brain metastasis accompany clinical symptom require treatment Subjects severe complication disease history Subjects unable take oral medication . Subjects treat drug strongly inhibit induce CYP3A4 may possibly use study . Scheduled surgery project course study . Positive human immunodeficiency virus ( HIV antibody ) test positive hepatitis B surface ( HBs antigen ) hepatitis C ( HCV antibody ) serum test . Subjects view investigator able comply protocol psychiatric physical disease include alcoholism drug addict Pregnant nursing subject Subjects participate another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
</DOC>